Oxytocin FAQ: common questions answered
A hormone used during childbirth; nasal social and weight-loss benefits remain unproven.
Also called: Pitocin, Syntocinon, OT, OXT, TTA-121.
Neuropeptides · Oxytocin-receptor agonist and uterotonic hormone · Evidence: Approved drug.
- Is Oxytocin FDA-approved? No. Injection approval does not cover nasal, under-the-tongue, mood, autism or weight-loss products. Compounded drugs are not FDA-approved.
- How do people take it? Under the skin, per injection; interval usually not stated. Source: reported by users, not an established dose.
- Can I take it with Bremelanotide / PT-141? People combine it with nasal oxytocin hoping to improve sexual desire and closeness. No controlled trial of this pairing was located. Combination safety is unknown. Reports cannot separate effects from either ingredient. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? No, it is not on the banned list (WADA 2026). IV infusions/injections above 100 mL per 12 hours are prohibited except during hospital treatment, surgery or clinical diagnostic investigations. M2.2 separately addresses total IV infusions or injections over 100 mL per 12 hours, except legitimate hospital treatment, surgical procedures or clinical diagnostic investigations.
- How do I store it once opened? UK diluted infusion: use immediately; normally no longer than 24 hours at 2–8°C unless aseptic conditions are validated. This is not a home-spray shelf life.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- PITOCIN- oxytocin injection, Par Health USA, LLC · DailyMed · 2026
- Search results summary, Health Canada · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Understanding the Risks of Compounded Drugs, FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Oxytocin 10 IU/ml Solution for infusion - Summary of Product Characteristics (SmPC), electronic medicines compendium · 2025
- Postpartum interventions to prevent postpartum haemorrhage, World Health Organization · 2025
- WHO recommendations on maternal and newborn care for a positive postnatal experience, World Health Organization · 2022
- Syntometrine, Phebra Pty Ltd · Australian Commission on Safety and Quality in Health Care · 2019
- PSUSA/00002263/201706 - periodic safety update report single assessment, EMA · 2018
- Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry, FDA · 2016
- Oxytocin (Aspen), Healthdirect Australia
- SYNTOCINON oxytocin 10 IU/1 mL injection ampoule (13383), Therapeutic Goods Administration
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.